Moreover, a PEGylated human fibroblast growth factor 21 (FGF21) analogue pegbelfermin has also been shown to significantly reduce liver fat fraction in patients with nonalcoholic steatohepatitis (102). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.